Theravance Biopharma buy marge
Summary
This prediction ended on 15.01.18 with a price of €24.34. Massive losses of -30.62% were the result for the BUY prediction by marge. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Theravance Biopharma | 0.000% | 0.000% | -15.591% | -34.583% |
| iShares Core DAX® | -0.145% | -2.221% | 11.782% | 13.867% |
| iShares Nasdaq 100 | 1.296% | 9.035% | 34.565% | 51.691% |
| iShares Nikkei 225® | 1.282% | 3.119% | 8.953% | 6.440% |
| iShares S&P 500 | 0.442% | 5.429% | 27.376% | 44.980% |
Comments by marge for this prediction
In the thread Theravance Biopharma diskutieren
TBPH: Revefenacin for Chronic Obstructive Pulmonary disease [COPD]
Mid trial safety data for COPD treatment via Revefenacin is expected mid 2017. TBPH developed Revefenacin in conjunction with Mylan (MYL).
Phase 2 and Phase 2b studies demonstrated clinically significant improvements in lung function in COPD patients. COPD progressively makes it harder to breathe over time and induces coughing fits. The most common cause of COPD is smoking, and over 12 million Americans have the disease. The National Institute of Health [NIH] estimates 12 million more Americans may have undiagnosed COPD. 120,000 people die each year from the disease, and although there are currently treatments to address the symptoms, a best in class drug from TBPH would be a major boon for the company and for those stuck with COPD.
Regarding their other projects, TBPH has a large, diverse pipeline researching treatments for a swath of infectious diseases, respiratory issues, gastrointestinal problems, and cardiovascular concerns.